

NIH Public Access

Author Manuscript

Helv Chim Acta. Author manuscript; available in PMC 2009 December 15.

Published in final edited form as: *Helv Chim Acta.* 1999 December 15; 82(12): 2160–2171.

Novel Nucleoside Analogues with Fluorophores Replacing the DNA Base

Christoph Strässler, Newton E. Davis¹, and Eric T. Kool¹

Department of Chemistry, University of Rochester, Rochester, NY 14627, USA

Abstract

We describe the preparation and fluorescence properties of a set of new nucleosides in which a known hydrocarbon or oligothiophene fluorophore replaces the DNA base at C(1) of the deoxyribose moiety (see 3a - f). These compounds are potentially useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. In addition, they may find use as fluorescent labels for nucleic-acid-based biomedical diagnostics methods. The fluorophores conjugated to deoxyribose at C(1) in the α -p-form include terphenyl, stilbene, terthiophene, benzoterthiophene, and pyrene. Also included is a non-fluorescent spacer in which cyclohexene replaces the DNA base. The nucleosides are derived from brominated fluorophore precursors and *Hoffer*'s 2-deoxy-3,5-di-*O*-(*p*-toluoyl)-p-ribofuranosyl chloride. The emission maxima of the free nucleosides range from 345 to 536 nm. Also described are the 5'- (dimethoxytrityl) 3'-*O*-phosphoramidite derivatives 5a - f, suitable for incorporation into oligonucleotides by automated synthesizers.

Introduction

Fluorescence methods are extremely widespread in chemistry and biology. They give useful information on structure, distance, orientation, complexation, and location for biomolecules [1]. In addition, time-resolved methods are increasingly used in measurements of dynamics and kinetics [2]. As a result, many strategies for fluorescence labeling of biomolecules, such as nucleic acids, have been developed [3]. In the case of DNA, one of the most convenient and useful methods for fluorescence labeling is to add a fluorescent moiety during the DNA synthesis itself; this avoids the extra steps required for post-synthesis labeling and purification. The majority of labels commonly used during DNA synthesis are attached to the DNA by tethers that are often 5 to 11 atoms long; these flexible tethers can at times be problematic, since they allow the dye to tumble independently of the DNA and make the location of the dye difficult to determine precisely [4]. There are very few examples of dye conjugates that hold the dye close to the DNA, thus avoiding these problems. Among the known dyes of this class are ethenodeoxyadenosine [5] and 9H-purin-2-amine deoxyriboside [6]. These latter two compounds have modified DNA bases that are themselves fluorescent, and they have found much use as probes of enzymatic activities such as DNA synthesis, editing, and repair [7–9].

We have taken a related approach to developing new fluorescent labels for DNA [10]. Rather than modifying an existing DNA base, however, we have simply replaced it by another flat aromatic structure, *i.e.*, by a hydrocarbon rather than by a heterocyclic N-

Correspondence to: Eric T. Kool.

Dedicated to Prof. Dr. Frank Seela on the occasion of his 60th birthday

¹Current address: Dept. of Chemistry, Stanford University, Stanford, CA 94305-5080, USA (fax: (650) 725-0259; kool@chem.stanford.edu)

containing base. This substitution is particularly attractive because it creates only a small perturbation to the natural DNA structure and allows for close interaction, including possible stacking, with the neighboring DNA helix. There are many known hydrocarbon-based fluorophores, many with high quantum yields and with varied excitation and emission characteristics. Moreover, their lack of functional groups makes them relatively simple to work with in preparing conjugates.

We previously reported early studies on the incorporation of 4-methyl-1*H*-indole, naphthalene, phenanthrene, and pyrene fluorophores at the C(1)-position of 2-deoxy-_D-ribose [10] [11]. In a similar strategy, *Coleman* and co-workers recently reported the substitution of a coumarin dye at C(1) [12]. Our 4-methyl-1*H*-indole derivative recently found use as a fluorescent reporter of DNA-repair activities [13]. In addition, the derivative with a pyrene moiety at C(1) in the α -_D-form has been shown to be useful in DNA diagnostics strategies, where it efficiently forms excimers with neighboring pyrene labels [14]. We demonstrated further that the corresponding pyrene derivative in the β -_D-form stabilizes DNA helices markedly (due to its low polarity) [15] [16], and that it can be enzymatically incorporated into the DNA helix [17]. Thus, this new nucleic acid labeling strategy is beginning to find useful applications.

In our ongoing studies, we wished to generate a series of new nucleosides with improved fluorescence characteristics, increasing the range of emission wavelengths over those we previously studied. Such compounds might be more generally useful in biophysical and diagnostics experiments. Here we report an expanded set of new fluorescent hydrocarbons and oligothiophenes conjugated to 2-deoxy-D-ribose. These new compounds significantly broaden the range of fluorescence properties available for automated incorporation into DNA.

Results and Discussion

We have previously described the preparation of *C*-nucleosides of type **3** by cadmium- or zinc-mediated reaction of *Grignard* derivatives of aromatic compounds of type **1** with *Hoffer*'s chlorosugar (= 2-deoxy-3,5-di-*O*-(*p*-toluoyl)-_D-ribofuranosyl chloride) (Scheme 1) [18] [19]. The primary product in this coupling reaction is the 1-coupled product of type **2** in the α -D-form generated with retention of configuration. Although the α -D-orientation is not the same as for natural β -D-nucleosides, α -D-nucleosides are also known to form DNA-like helices [20], and models suggest that they can still interact well with natural bases in neighboring positions. Our approach in this study was to choose a set of known fluorophores for which a bromo derivative **1** was readily available and which had varied absorption and emission characteristics.

Besides this set of five fluorophores (see 3a - e), we also prepared a *C*-nucleoside 3f with cyclohexene at the 1-position as a nonfluorescent spacer. Fluorophores are usually quenched by neighboring DNA bases [21], and we observed this to be the case for the pyrene derivative 3d as well [10]. Thus, we designed the cyclohexene compound to be inserted, if desired, between fluorophores and natural DNA bases to possibly limit any quenching that might occur. Cyclohexene was chosen rather than saturated cyclo-hexane because the former has sp^2 geometry at the point of attachment, the same as the other analogues and the natural bases.

Thus, we purchased 1-bromopyrene (1d) and prepared bromobenzoterthiophene 1b [22], 4-bromo-1,1':4',1" terphenyl (1c) [23], 4-bromostilbene (= 4-bromo-1,1'-(ethene-1,2-diyl)bis[benzene]; 1e) [24], and 1-bromocyclohexene (1f) [25] according to literature procedures. The 5-bromo-2,2': 4',2"-terthiophene (1a) was prepared from 2-bromothiophene

via **6** and **7** as shown in Scheme 2. Subsequent coupling reactions with *Hoffer*'s chlorosugar [26] were performed generally as described previously, with moderate to modest success, giving yields of 23 - 55% for the coupled products **2**. The pyrene nucleoside **3d** was also prepared by this approach, as previously described [10]. The toluoyl protecting groups on all the nucleosides **2a** – **f** were then removed to generate the free nucleosides **3a** – **f**. These were examined for their fluorescence characteristics (see below). For future studies, in which these fluorophores are incorporated into DNA, we carried on with the nucleosides **3a** – **f** to prepare the 5'-(dimethoxytrityl)-protected nucleosides **4a** – **f** and then the 3'-phosphoramidites **5a** – **f**.

The syntheses proceeded as expected, except in the benzoterthiophene case. During the synthesis of the nucleosides **2b** and **3b**, significant decomposition was observed. To determine whether it was a thermal or a photodecomposition, an NMR sample of the di-O-toluoylnucleoside **2b** in CDCl₃ was kept exposed to fluorescent room light, and a similar sample was kept wrapped in aluminium foil. ¹H-NMR Spectra were measured immediately after preparation of the two samples, and then after 1 day and after 7 days. We found that the spectrum of the aluminium-foil-protected sample remained unchanged (not shown), whereas decomposition of the nucleoside **2b** could be observed in the light-exposed sample after 7 days. Subsequently, we carried out all experiments with the benzoterthiophene derivatives and limited light exposure by covering glassware with aluminium foil. The best success in coupling **1b** with *Hoffer*'s chlorosugar was observed with the debrominated form of **1b**, *i.e.*, direct deprotonation formed the organolithium species which was then exchanged with CdCl₂ to give the analogous organocadmium-mediated reaction.

Absorption and emission spectra of 10 μ_M solutions of the deprotected nucleosides **3a** – **c,e** and of the earlier described pyrene nucleoside **3d** [10] were measured in deoxygenated MeOH at room temperature. Excitation spectra were also measured (data not shown) at the emission maxima, and the spectra were identical to the absorption curves shown in the Figure. The quantum yields for the five compounds (Table) were determined with quinine sulfate and fluorescein as standards. The results show absorption maxima ranging from 285 nm for terphenyl derivative **3c** to 437 nm for benzoterthiophene derivative **3b**, which appears yellow-orange in solution under incandescent light. Emission maxima range from 345 nm for terphenyl derivative **3c** (a violet-blue fluorophore) to 536 nm for the benzoterthiophene derivative **3b** (which fluoresces bright yellow).

Not surprisingly, there is little difference in the absorbance and fluorescence spectra of the nucleosides 3a - e and the corresponding free fluorophores. The quantum yields of the terthiophene nucleoside **3a** and the free terthiophene **7** are about the same as the reported quantum yield for free terthiophene [27], and the quantum yield of pyrene nucleoside 3d is similar to that of pyrene-1-butanoic acid. However, the quantum yield we measured is ca. 20-fold smaller than the quantum yield reported by Telser et al. [28] for pyrenebutanoate. They used a different value for the quantum yield of quinine sulfate (0.70 instead of 0.55)and measured the quantum yield in an aqueous buffer, but those differences do not seem sufficient to explain this difference. The sharpness of the absorption and emission lines for this compound may have caused difficulties in accurately measuring a maximum value. The quantum yield we measured for the stilbene nucleoside 3e is ca. 50% smaller than the quantum yield reported by Lewis et al. [29] for a stilbenedicarboxamide at the excitation wavelength of 330 nm, which was determined in a 4 : 1 aqueous EtOH solution, using a phenanthrene standard. The quantum yields for the benzoterthiophene and terphenyl nucleosides **3b** and **3c**, respectively are high compared with the other nucleosides, but no literature reference could be found for comparison.

We expect that some of these nucleoside analogues will have a range of uses. There are several colors to choose from, which allows for possible multiplex use in diagnostics studies. In addition, some of the free fluorophores incorporated here are known to undergo excimer formation when two are present at high local concentrations. We expect that excimer, exciplex, and other forms of energy transfer might be observed for some of these nucleosides when placed in proximity with one another. Such studies are currently underway.

Experimental Part

General

Solvents used as reaction media were purified and dried by distillation over CaH₂ (pyridine, MeCN, and CH₂Cl₂), Na (THF), or MeONa (MeOH) before use. Chemicals were purchased from *Acros*, *Aldrich*, *Alfa-Aesar*, *Lancaster*, *Fisher*, or *J. T. Baker*. Flash chromatography (FC): silica gel *Merck* 60, 0.040 – 0.063 mm. ¹H-NMR (400 MHz) and ¹³C-NMR (100 MHz): in CDCl₃ unless otherwise stated; *Bruker-Avance-400* spectrometer; chemical shifts in ppm rel. to SiMe₄, coupling constants *J* in Hz. High resolution mass spectral analyses (HR-MS) were performed by the University of California-Riverside mass spectrometry facility. EI-MS: *HP 5973* mass selective detector. Abbreviations: DMAP = 4- (dimethylamino)pyridine. (MeO)₂Tr = 4,4'-dimethoxytrityl.

General Procedure A (G.P. A)

A soln. of the aryl bromide **1** in dry THF was slowly added to Mg turnings in dry THF. To start the *Grignard* reaction, a few drops of 1,2-dibromoethane were added, and the mixture was slightly heated. After complete addition of the aryl bromide soln., the mixture was stirred for 2 h at 50°. CdCl₂ was then added and the mixture stirred for 2 h under reflux. The mixture was cooled to r.t., and a soln. of 2-deoxy-3,5-di-*O*-(*p*-toluoyl)-_D-ribofuranosyl chloride [22] in THF was added. After stirring for 16 h at r.t., the solvent was evaporated and the residue suspended in CH₂Cl₂ and washed twice with 10% NH₄Cl soln. The aq. layers were extracted with CH₂Cl₂ and the org. layers dried (MgSO₄) and evaporated. Purification by FC (hexanes/AcOEt 6 : 1) gave the pure α -D-anomers **2** (the β -D-anomers as minor products were not isolated).

General Procedure B (G.P. B)

Freshly prepared 0.5_{M} NaOMe in MeOH was added to a soln. of the protected nucleoside **2** in MeOH/CH₂Cl₂ 1 :1. After stirring for 4 h at r.t., crystalline NH₄Cl was added, and the solvent was evaporated. Purification by FC (AcOEt) gave the pure deprotected nucleosides.

General Procedure C (G.P. C)

The deprotected nucleoside **3** was co-evaporated twice with pyridine and then dissolved in pyridine/CH₂Cl₂. Then, 4,4'-dimethoxytrityl chloride ((MeO)₂Tr-Cl), ⁱPr₂EtN, and a catalytic amount of 4-(dimethylamino)pyridine (DMAP) were added, and the mixture was stirred for 4 - 8 h at r.t. Then the solvents were evaporated, and the residue was purified by FC (hexanes/AcOEt 4 :1 \rightarrow 1.5 : 1, preequilibrated with hexanes containing 5% Et₃N): **4**.

General Procedure D (G.P. D)

To a soln. of the $(MeO)_2$ Tr-protected nucleoside **4** in CH₂Cl₂, 2-cyanoethyl diisopropylphosphoramidochloridite and ⁱPr₂EtN were added, and the mixture was stirred for 5 h at r.t. The solvent was evaporated and the residue purified by FC (hexanes/AcOEt 3 : 1, preequilibrated with hexanes/AcOEt 3 :1 containing 5% Et₃N): **5**.

1. Terthiophene Nucleoside. 5-Bromo-2,2'-bithiophene (6)—A soln. of 2-

bromothiophene (4.967 g, 24.92 mmol) in dry THF (5 ml) was added dropwise to Mg turnings (752 mg, 30.94 mmol) and a small I₂ crystal in dry THF (25 ml). When *ca.* 1 ml of the bromothiophene soln. was added, the reaction started, and the mixture was kept under reflux. After the addition, the mixture was stirred for 1 h under reflux. The mixture was then transferred with a syringe to an addition funnel and added slowly during 3 h to an ice-cooled mixture of 2,5-dibromothiophene (8.206 g, 33.91 mmol) and [1,1'-

bis(diphenylphosphino)ferrocene]dichloropalladium(II) ([PdCl₂(dppf)₂]; 250 mg, 0.306 mmol; 1 : 1 complex with CH₂Cl₂ in dry THF (50 ml). This mixture was stirred for 2 h at 0° and for 16 h at r.t. The solvent was evaporated and the residue suspended in AcOEt and washed with sat. NaHCO₃ soln. and brine. The aq. layers were extracted with AcOEt and the org. layers dried (MgSO₄) and evaporated. Purification by FC (hexanes) gave 4.229 g (57%) of **6** and 1.216 g (16%) of 2,2': 5',2"-terthiophene (**7**) as yellow solids.

<u>Data of 6:</u> ¹H-NMR: 7.22 (*dd*, *J* = 5.2, 0.8, 1 H); 7.11 (*dd*, *J* = 3.6, 0.8, 1 H); 7.00 (*dd*, *J* = 5.2, 3.6, 1 H); 6.96 (*d*, *J* = 3.9, 1 H); 6.91 (*d*, *J* = 3.9, 1 H). ¹³C-NMR: 138.9, 136.4 (2*s*); 130.6, 127.8, 124.8 (3*d*); 124.3 (*s*); 124.0, 123.8 (2*d*). EI-MS: 246 (100, M^+ (⁸¹Br)), 244 (88, M^+ (⁷⁹Br)), 165 (39), 121 (53).

5-Bromo-2,2': 5',2''-terthiophene [23] (1a): From **6**: A soln. of **6** (3.052 g, 12.45 mmol) in dry THF (20 ml) was added dropwise to Mg turnings (332 mg, 13.66mmol) and a small I₂ crystal in dry THF (10 ml). To start the *Grignard* reaction, the mixture had to be heated under reflux. After the addition, the mixture was stirred for 2 h under reflux. Then it was cooled to r.t., transferred with a syringe to an addition funnel, and added dropwise during 2 h to a mixture of 2,5-dibromothiophene (3.031 g, 12.53 mmol) and [PdCl₂(dppf)₂] (113 mg, 0.138 mmol; 1 :1 complex with CH₂Cl₂) in dry THF (50 ml) at -20° . This mixture was stirred for 2 h at -20° and then for 14 h at r.t. The solvent was evaporated and the residue dissolved in CH₂Cl₂ and washed with 5% HCl soln. and brine. The aq. layers were extracted with CH₂Cl₂ and the org. layers dried (MgSO₄) and evaporated. Purification by FC (hexane) gave 1.597 g (39%) of **1a**.

From 7: *N*-Bromosuccinimide (3.147 mg, 17.681 mmol) was added in portions during 5 h to a soln. of 7 (4.315 g, 17.373 mmol) in DMF (10 ml) at -20° . After *ca*. 90 min, a precipitate was formed. After stirring for 14 h at r.t., the mixture was dissolved in CH₂Cl₂ (300 ml) and washed with 1_{N} HCl (2 × 100 ml). The aq. layers were extracted with CH₂Cl₂ and the org. layers dried (MgSO₄) and evaporated. Purification by FC (hexanes) gave 5.222 g (92%) of **1a**. Yellow solid. ¹H-NMR: 7.23 (*dd*, *J* = 5.2, 1.0, 1 H); 7.17 (*dd*, *J* = 3.6, 1.0, 1 H); 7.07 (*d*, *J* = 3.7, 1 H); 7.02 (*dd*, *J* = 5.3, 3.6, 1 H); 7.01 (*d*, *J* = 3.6, 1 H); 6.98 (*d*, *J* = 3.9, 1 H); 6.91 (*d*, *J* = 3.8, 1 H). ¹³C-NMR (CDCl₃): 138.6; 136.8; 136.7; 135.0; 130.7; 127.9; 124.7; 124.5; 124.3; 123.9; 123.7; 111.0. EI-MS: 328 (100, M^+ (⁸¹Br)), 326 (88, M^+ , (⁷⁹Br)), 247 (15), 203 (32).

(1S)-1,4-Anhydro-1,2-dideoxy-([2,2':5',2"-terthiophen]-5-yl)-3,5-di-O-(p-toluoyl)-perythro-pentitol (2a): According to *G.P. A* with 1a (1.809 g, 5.528 mmol) in THF (15 ml), Mg turnings (141 mg, 5.802 mmol) in THF (2 ml), CdCl₂ (1.021 g, 5.569 mmol) and *Hoffer*'s chlorosugar (2.144 g, 5.514 mmol) in THF (10 ml); 1.816 g (55%) of 2a. Yellow foam. ¹H-NMR: 7.97, 7.83 (2*d*, J = 8.2, 4 arom. H); 7.24 - 7.16 (*m*, 6 arom. H); 7.07 (*d*, J =3.8, 1 arom. H); 7.03 - 7.01 (*m*, 3 arom. H); 6.91 (*d*, J = 3.5, 1 arom. H); 5.62 (*m*, H – C(3)); 5.57 (*dd*, J = 7.5, 4.9, H – C(1)); 4.70 (*m*, H – C(4)); 4.58 (*m*, 2 H – C(5)); 2.96, 2.47 (2*m*, 2 H – C(2)); 2.41, 2.39 (2*s*, 2 *Me*C₆H₄). ¹³C-NMR: 166.3, 166.1 (2 C = O); 145.5, 144.0, 143.9, 137.1, 136.7, 136.1 (6*s*, 7 arom. C); 129.73, 129.71, 129.1, 129.0, 127.9 (5*d*, 9 arom. CH); 127.0, 126.8 (2*s*, 2 arom. C); 125.0, 124.5, 124.3, 124.1, 123.6, 123.2 (6*d*, 6 arom.

CH); 82.1, 76.8, 76.2 (3*d*, CH(1), CH(3), CH(4)); 64.4, 40.3 (2*t*, CH(5), CH₂(2)); 21.7 (*q*, CH₃C₆H₄). HR-MS: 600.1109 (C₃₃H₂₈O₅S₃⁺, M^+ ; calc. 600.1099).

(1S)-1,4-Anhydro-1,2-dideoxy-1-([2,2':5',2"-terthiophen]-5-yl)-p-erythro-pentitol (3a): According to *G.P. B* with **2a** (535 mg, 0.891 mmol) and $0.5_{\rm M}$ NaOMe in MeOH (1 ml, 0.5 mmol) in MeOH/CH₂Cl₂ 1 : 1 (5 ml): 235 mg (72%) of **3a**. Yellow crystals. ¹H-NMR: 7.25 - 6.93 (*m*, 7 arom. H); 5.35 (*m*, H – C(1)); 4.49, 4.10 (2*m*, H – C(3), H – C(4)); 3.86, 3.76 (2*m*, 2 H – C(5)); 2.75, 2.26 (2*m*, 2 H – C(2)). ¹³C-NMR (D₅)pyridine): 148.2, 137.4, 136.9, 136.3 (4s); 128.6, 125.4, 125.1, 124.7, 124.4, 123.9 (6*d*, 7 arom. CH); 87.7, 76.1, 72.8 (3*d*, CH(1), CH(3), CH(4)); 63.0, 44.8 (2*t*, CH(5), CH(2)). HR-MS: 364.0273 (C₁₇H₁₆O₃S₃⁺, *M*⁺; calc. 364.0262).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1([2,2':5',2''-terthiophen]-5yl)-d-erythro-pentitol (4a): According to *G.P.* with *C*, (MeO)₂Tr-Cl (269 mg, 0.794 mmol), ⁱPr₂EtN (115 µl, 0.672 mmol), a spatula tip of DMAP, **3a** (161 mg, 0.442 mmol), and pyridine/CH₂Cl₂1 : 1 (8 ml) 6 h. Purification gave 268 mg (91%) of **9a**. Yellowish foam. ¹H-NMR: 7.50 (d, J = 7.5, 2 arom. H); 7.41 - 7.19, 7.10 - 7.04 (2m, 13 arom. H); 6.95 (d, J = 3.5, 1 arom. H); 6.88 (d, J = 8.8, 4 arom. H); 5.36 (t, J = 7.0, H – C(1)); 4.45 (m, H – C(3)); 4.21 (m, H – C(4)); 3.82 (s, 2 MeO); 3.38, 3.27 (2m, 2 H – C(5)); 2.75, 2.21 (2m, 2 H – C(2)). ¹³C-NMR: 158.5, 145.9, 144.7, 137.1, 136.7, 136.2, 136.1, 135.9 (8s, 10 arom. C); 130.0, 128.1, 127.9, 126.9, 125.0, 124.5, 124.3, 124.2, 123.7, 123.3, 113.2 (11d, 20 arom. CH); 86.4 (s, 1 C); 84.4, 75.9, 74.8 (3d, CH(1), CH(3), CH(4)); 64.5 (t, CH₂(5)); 55.2 (q, 2 MeO); 42.9 (t, CH₂(2')). HR-MS: 689.1430 (C₃₈H₃₄NaO₅S₃⁺, [M + Na]⁺; calc. 689.1466).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-([2,2':5',2"-terthiophen]-5yl)-p-erythro-pentitol 3-(2-(Cyanoethyl Diisopropylphosphoramidite) (5a): According to G.P. D, with 2-cyanoethyl diisopropylphosphoramidochloridite (172 mg, 0.726 mmol), ⁱPr₂EtN (350 µl, 2.044 mmol), **4a** (313 mg, 0.469 mmol), and CH₂Cl₂ (5 ml). Purification gave 321 mg (79%) of **5a**. Yellowish foam. ¹H-NMR (mixture of 2 diastereoisomers): 7.53 - 7.50, 7.42 - 7.17, 7.09 - 7.01, 6.93 - 6.91, 6.86 - 6.82 (5m, 20 arom. H); 5.43 (m, H - C(1)); 4.57, 4.34 (2m, H - C(3), H - C(4)); 3.81, 3.80 (2s, 2 MeO); 3.72 -3.48, 3.38 - 3.27, 3.17 - 3.13 (3m, 2 Me₂CHN), OCH₂CH₂CN, 2 H - C(5)); 2.75 (m, 1 H -C(2)); 2.56 - 2.51 (*m*, OCH₂CH₂CN); 2.37 (*m*, 1 H – C(2)); 1.17 - 1.03 (*m*, 2 *Me*₂CHN). ¹³C-NMR: 158.4; 146.1; 144.9, 137.1, 136.4, 136.1, 136.0 (7*s*, 10 arom. C); 130.1, 128.2, 127.9, 127.8, 126.7, 124.9, 124.4, 124.3, 124.0, 123.6, 123.2 (11*d*, 16 arom. CH); 117.5 (s, CN); 113.1 (d, 4 arom. CH); 86.1 (s, 1 C); 84.7, 76.3 (2d, CH(1), CH(4)); 75.0, 74.8 (2d, CH(3)); 63.8 (t, CH₂(5)); 58.2, 58.1 (2t, OCH₂CH₂CN); 55.2 (q, 2 MeO); 43.2, 43.1 (2d, 2 Me₂CHN); 42.4 (t, CH₂(2)); 24.6, 24.5, 24.4, 24.3 (4q, 2 Me₂CHN); 20.1, 20.0 (2*t*, OCH₂CH₂CN). HR-MS: 889.2532 (C₄₇H₅₁N₂NaO₆PS₃⁺, [*M* + Na]⁺; calc. 889.2545).

2. Benzoterthiophene Nucleoside. (1S)-1,4-Anhydro-1,2-dideoxy-1-{5-[3-(thiophen-2-yl)benzo[c]thiophen-1-yl]thiophen-2-yl}-3,5-di-O-(p-toluoyl)-D-

erythro-pentitol (2b)—The reaction was performed in the absence of light (flasks wrapped in Al-foil). To a soln. of 1,3-di(thiophen-2-yl)benzo[*c*]thiophene [22] in THF (40 ml) at -68° , 2.5_M BuLi in hexane (1 ml, 2.5 mmol) was slowly added and stirred for 90 min. CdCl₂ (281 mg, 1.533 mmol) was added at -68° and the mixture allowed to warm up to r.t. and stirred for 2 h at r.t. A soln. of *Hoffer*'s chlorosugar (831 mg, 2.137 mmol) in THF (20 ml) was added and stirred for 16 h. Then the solvent was evaporated, the residue dissolved in CH₂Cl₂, the soln. washed twice with 10% NH₄Cl soln. The aq. layers were extracted with CH₂Cl₂ and the org. layers dried (MgSO₄) and evaporated. Purification by FC (hexane/AcOEt 7 : 1) gave 678 mg (49%) of **2b** and 231 mg (37%) of recovered unreacted 1,3-

di(thiophen-2-yl)benzo[*c*]thiophene. **2b**: ¹H-NMR: 8.01 - 7.85 (*m*, 6 arom. H); 7.41 - 7.06 (11*m*, 13 arom. H); 5.68 - 5.64 (*m*, H - C(1), H - C(3)); 4.77, 4.62 (2*m*, H - C(4), 2 H - C(5)); 3.02 (*m*, H - C(2)); 2.45 (*s*, $MeC_{6}H_{4}$); 2.57 (*m*, H - C(2)); 2.44 (*s*, $MeC_{6}H_{4}$); 2.38 (*s*, $MeC_{6}H_{4}$). ¹³C-NMR: 166.4, 166.1 (2 C = O); 143.9, 143.8, 141.6, 140.6, 140.1, 139.7 (6*s*, arom. C); 129.7, 129.6, 129.1, 129.0, 128.8, 127.5, 127.4, 127.1, 127.0 (10*d*, 19 arom. CH); 126.8 (*s*, arom. C); 126.1 (*d*, 2 arom. CH); 82.2, 80.0, 76.4 (3*d*, CH(1), CH(3), CH(4)); 64.6, 40.3 (2*t*, CH₂(5), CH₂(2)); 21.67, 21.63 (2*q*, 2*C*H₃C₆H₄). HR-MS: 651.1358 (C₃₇H₃₁O₅S₃⁺, [*M* + H]⁺; calc. 651.1334).

(1S)-1,4-Anhydro-1,2-dideoxy-1-{5-[3-(thiophen-2-yl)benzo[c]thiophen-1-

yl]thiophen-2-yl}-berythro-pentitol (3b): According to *G.P. B*, in the absence of light (flasks wrapped in Al-foil), with **2b** (548 mg, 0.842 mmol) and 0.5_{M} NaOMe in MeOH (850 µl, 0.425 mmol) in MeOH/CH₂Cl₂ 1 :1 (5 ml): 243 mg (70%) of 3b. Dark yellow solid. ¹H-NMR ((D₈)THF): 7.97 - 7.91 (*m*, 2 arom. H); 7.48 (*d*, *J* = 4.9, 1 arom. H); 7.38 (*d*, *J* = 3.2, 1 arom. H); 7.24 - 7.21, 7.15 - 7.10, 7.02 - 7.00 (3*m*, 5 arom. H); 5.28 (*t*, *J* = 7.4, H – C(1)); 4.41, 4.29, 3.90 (3*m*, H – C(3), H – C(4), 2 OH); 3.67 - 3.55 (*m*, 2 H – C(5)); 2.66, 2.08 (*m*, 2 H – C(2)). ¹³C-NMR ((D₈)THF): 146.8, 133.4, 133.3, 133.1, 132.3 (5*s*, 5 arom. C); 125.9 (*d*, 1 arom. CH); 124.9, 124.0 (2*s*, 2 arom. C); 123.7, 123.5, 123.0, 122.8, 122.7, 122.4, 119.5, 119.3 (8*d*, 8 arom. CH); 84.5, 73.7, 70.1 (3*d*, CH(1), CH(3), CH(4)); 60.3, 42.1 (2*t*, CH₂(5), CH₂(2)).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-{5-[3-(thiophen-2-

yl)benzo[c]thiophen-1-yl]thiophen-2-yl}-**erythro-pentitol (4b):** According to *G.P. C*, in the absence of light (flasks wrapped in Al-foil), with (MeO)₂Tr-Cl (210 mg, 0.620 mmol), ⁱPrEtN (180 µl, 1.051 mmol), a spatula tip of DMAP, **3b** (104 mg, 0.251 mmol), and pyridine/CH₂Cl₂ 1 : 1 (5 ml), 3 days. Purification gave 94 mg (52%) of **4b**. Dark yellow foam. ¹H-NMR: 7.99 - 7.95 (*m*, 2 arom. H); 7.49 - 7.15 (*m*, 15 arom. H); 7.06 (*d*, *J* = 3.6, 1 arom. H); 6.87 (*d*, *J* = 8.8, 4 arom. H); 5.42 (*t*, *J* = 7.1,H – C(1)); 4.47, 4.21 (2*m*, H – C(3),H – C(4)); 3.82 (*s*, 2 MeO); 3.46 (*dd*, *J* = 9.5, 4.4, H – C(5)); 4.21 (*dd*, *J* = 9.5, 6.0, H – C(5)); 2.81 (*m*, 1 H – C(2)); 2.31 - 2.24 (*m*, 1 H – C(2), 1 OH); 2.03 (*d*, *J* = 5.0, 1 OH). ¹³C-NMR: 158.5, 146.8, 144.7, 135.9, 135.6, 135.3, 135.2, 135.1 (8*s*, 10 arom. C); 130.0, 128.1, 127.9, 126.5 (*4d*, 9 arom. CH); 126.6, 126.4 (2*s*, 2 arom. C); 125.6, 125.5, 125.2, 125.1, 124.8, 121.6, 121.5, 113.2 (8*d*, 13 arom. CH); 86.4 (*s*, 1 C); 84.3, 75.9, 74.9 (3*d*, CH(1), CH(3). CH(4)); 64.5 (*t*,CH₂(5)); 55.2 (*q*, 2 MeO); 42.9 (*t*, CH₂(2)).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-{5-[3-(thiophen-2-yl)benzo[c]thiophen-1-yl]thiophen-2-yl}-p-erythro-pentitol 3-(2-cyanoethyl

Disopropylphosphoramidite) (**5b**): According to *G.P. D*, in the absence of light (flasks wrapped in Al-foil), with 2-cyanoethyl diisopropylphosphoramidochloridite (166 mg, 0.701 mmol), ⁱPr₂EtN (300 µl, 1.75 mmol), **4b** (318 mg, 0.444 mmol), and CH₂Cl₂ (10 ml). Purification gave 302 mg (74%) of **5b**. Dark yellow foam. ¹H-NMR (mixture of 2 diastereoisomers): 7.73 - 7.67, 7.59 - 7.25, 6.91 - 6.87 (*3m*, 26 arom. H); 5.33, 4.65, 4.43 (*3m*, H – C(1), H – C(3), H – C(4)); 3.84, 3.83 (2*s*, 2 MeO); 3.66 - 3.35, 3.26 - 3.23 (2*m*, 2 Me₂CHN, OCH₂CH₂CN, 2 H – C(5)); 2.81 (*m*, 1 H – C(2)); 2.50 - 2.18 (*m*, OCH₂CH₂CN, 1 H – C(2)); 1.20 - 1.06 (*m*, 2 *Me*₂CHN). ¹³C-NMR: 158.4, 144.9, 142.5, 142.2, 140.7, 140.0, 139.9, 139.7, 139.5, 136.1 (10*s*, 10 arom. C); 130.1, 128.8, 128.3, 127.8, 127.5, 127.40, 127.36, 127.31, 127.0, 126.9, 126.7, 126.5, 126.4, (14*d*, 22 arom. CH); 117.6, 117.5 (2*s*, CN); 113.1 (*d*, 4 arom. CH); 86.1 (*s*, 1 C); 84.8, 79.9 (2*d*, CH(1), CH(4)); 75.7, 75.2 (2*d*, CH(3)); 64.3, 64.0 (2*t*, CH₂(2)); 24.5, 24.4, 24.3 (3*q*, 2 *Me*₂CHN); 20.2, 20.1 (2*t*, OCH₂CH₂CN). HR-MS: 916.2831 (C₅₃H₅₇N₂NaO₆P⁺, [*M* + Na]⁺; calc. 916.2803).

3. Terphenyl Nucleoside. (1S)-1,4-Anhydro-1,2-dideoxy-1-([1,1': 4',1"terphenyl]-4-yl)-3,5-di-O-(p-toluoyl)-p-erythro-pentitol (2c)-A soln. of 1,2dibromoethane (2.3 ml, 26.7 mmol) in THF (50 ml) was slowly added to a mixture of Mg turnings (1.131 g, 46.54 mmol) in THF (100 ml) at r.t. After addition of ca. 5 ml of the dibromoethane soln., the *Grignard* reaction started. Then 4-bromo-1,1': 4',1"-terphenyl (1c, 5.433 g, 17.57 mmol) was added to the suspension, and the rest of the dibromoethane solution was added slowly during 40 min at 50°. After stirring for 3 h, CdCl₂ (2.213 g, 12.07 mmol) was added and the mixture was stirred for 2 h under reflux. After cooling to r.t., a soln. of the chlorosugar (6.832 g, 17.57 mmol) in THF (50 ml) was added, and the mixture was stirred for 16 h at r.t. Then CH₂Cl₂ (200 ml) was added and the mixture washed twice with 10% NH₄Cl soln. The aq. layers were extracted with CH₂Cl₂/THF 1 :1 and the org. layers dried (MgSO₄) and evaporated. Purification by FC (hexane/AcOEt 7 : 1) gave 2.339 g (23%) of **2c**. White powder. ¹H-NMR: 8.02 (d, J = 8.0, 2 arom. H); 7.73 - 7.66, 7.57 - 7.48, 7.42 - 7.39 (3*m*, 13 arom. H); 7.28, 7.17 (2*d*, J = 8.9, 4 arom. H); 5.66, 5.48 (2*m*, H – C(1), H - C(3); 4.77, 4.64 (2*m*, H - C(4), 2 H - C(5)); 3.01 (*m*, H - C(2)); 2.45 (*s*, $MeC_{6}H_{4}$); 2.43 (*m*, H – C(2)); 2.40 (*s*, *Me*C₆H₄). ¹³C-NMR: 166.4, 166.1 (2 C – O); 143.9, 143.8, 141.6, 140.6, 140.1, 139.7 (6s, arom. C); 129.7, 129.6, 129.1, 129.0, 128.8, 127.5, 127.4, 127.1, 127.0 (10d, 19 arom. CH); 126.8 (s, arom. C); 126.1 (d, 2 arom. CH); 82.2, 80.0, 76.4 (3d, CH(1), CH(3), CH(4)); 64.6, 40.3 (2t, CH₂(5), CH₂(2)); 21.67, 21.63 (2q, 2 CH₃C₆H₄). HR-MS: 582.2427 (C₃₉H₃₄O₅⁺, *M*⁺; calc. 582.2406).

(1S)-1,4-Anhydro-1,2-dideoxy-1-([1,1': 4',1"-terphenyl]-4-yl)-p-erythro-pentitol (3c): According to *G.P. B*, with 2c (427 mg, 0.732 mmol) and 0.5_{M} NaOMe in MeOH (730 µl,

0.365 mmol) in MeOH/CH₂Cl₂ 1 : 1 (5 ml): 201 mg (79%) of **3c**. White powder. ¹H-NMR ((D₈)THF): 7.70 - 7.61, 7.48 - 7.39, 7.33 - 7.28 (3*m*, 13 arom. H); 5.05 (*m*, H – C(1)); 4.37, 4.16, 3.90, 3.82, 3.65, 3.60 (6*m*, H – C(3), H – C(4), 2 H – C(5), 2 OH)); 2.61, 1.86 (2*m*, 2 H – C(2)). ¹³C-NMR ((D₅)pyridine): 144.1, 140.9, 140.2, 139.6 (4*s*, arom. C); 129.4, 127.9, 127.8, 127.3, 127.2, 127.1 (6*d*, arom. CH); 88.0, 79.8, 73.1 (3*d*, H – C(1), H – C(3), H – C(4)); 63.3, 45.1 (2*t*, CH₂(5), CH₂(2)). HR-MS: 346.1553 (C₂₃H₂₂O₃⁺, *M*⁺; calc. 346.1569).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-([1,1': 4',1"-terphenyl]-4-

yl)-**p**-**erythro-pentitol (4c):** According to *G.P. C* (MeO)₂Tr-Cl (135 mg, 0.398 mmol), ⁱPr₂EtN (70 μl, 0.409 mmol), a spatula tip of DMAP, **3c** (94 mg, 0.271 mmol), and pyridine/CH₂Cl₂ 1 :1 (4 ml), for 5 h. Purification gave 144 mg (82%) of **4c**. White foam. ¹H-NMR: 7.72 - 7.66, 7.55 - 7.25 (2*m*, 22 arom. H); 6.89 (*d*, *J* = 8.9, 4 arom. H); 5.23 (*t*, *J* = 7.4, H – C(1)); 4.50, 4.26 (2*m*, H – C(3), H – C(4)); 3.83 (*s*, 2 MeO); 3.45 (*dd*, *J* = 9.5, 4.6, H – C(5)); 3.30 (*dd*, *J* = 9.5, 6.0, H – C(5)); 2.77, 2.12 (2*m*, 2 H – C(2)). ¹³C-NMR: 158.5, 144.8, 142.1, 140.7, 140.1, 139.8, 139.7, 135.9 (8*s*, 10 arom. C); 130.0, 128.8, 128.1, 127.9, 127.5, 127.4, 127.3, 127.1, 127.0, 126.8, 126.3, 113.2 (12*d*, 26 arom. CH); 86.4 (*s*, 1 C); 84.5, 79.5, 75.2 (3*d*, CH(1), CH(3), CH(4)); 64.7 (*t*, CH₂(5)); 55.2 (*q*, 2 MeO); 43.1 (*t*, CH₂(2)). HR-MS: 671.2786 (C₄₄H₄₀NaO₅⁺, [*M* + Na]⁺; calc. 671.2773).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-([1,1':4',1"-terphenyl]-4yl)-_p-erythro-pentitol 3-(2-Cyanoethyl Diisopropylphosphoramidite) (5c): According to *G.P. D*, with 2-cyanoethyl diisopropylphosphoramidochloridite (276 mg, 1.166 mmol) and ⁱPr₂EtN (500 µl, 2.92 mmol) were reacted with 4c (494 mg, 0.761 mmol) in CH₂Cl₂ (10 ml). Purification gave 554 mg (86%) of 5c. White foam. ¹H-NMR (mixture of 2 diastereoisomers): 7.73 - 7.67, 7.59 - 7.25, 6.91 - 6.87 (3m, 26 arom. H); 5.33, 4.65, 4.43 (3m, H – C(1), H – C(3), H – C(4)); 3.84, 3.83 (2s, 2 MeO); 3.66 - 3.35, 3.26 - 3.23 (2m, 2 Me₂CHN, OCH₂CH₂CN, 2 H – C(5)); 2.81 (m, 1 H – C(2)); 2.50 - 2.18 (m, OCH₂CH₂CN, 1 H – C(2)); 1.20 - 1.06 (m, 2 Me₂CHN). ¹³C-NMR: 158.4, 144.9, 142.5, 142.2, 140.7, 140.0, 139.9, 139.7, 139.5, 136.1 (10s, 10 arom. C); 130.1, 128.8, 128.3, 127.8, 127.5,

127.40, 127.36, 127.31, 127.0, 126.9, 126.7, 126.5, 126.4 (14*d*, 22 arom. CH); 117.6, 117.5 (2*s*, CN); 113.1 (*d*, 4 arom. CH); 86.1 (*s*, 1 C); 84.8, 79.9 (2*d*, CH(1), CH(4)); 75.7, 75.2 (2*d*, CH(3)); 64.3, 64.0 (2*t*, CH₂(5)); 58.3, 58.1 (2*t*, OCH₂CH₂CN); 55.2 (*q*, 2 MeO); 43.2, 43.1 (2*d*, 2 Me₂CHN); 42.5 (*t*, CH₂(2)); 24.5, 24.4, 24.3 (3*q*, 2 Me_2 CHN); 20.2, 20.1 (2*t*, OCH₂CH₂CN). HR-MS: 871.3846 (C₅₃H₅₇N₂NaO₆P⁺, [*M* + Na]⁺; calc. 871.3852).

4. Stilbene Nucleoside

(1S)-1,4-Anhydro-1,2-dideoxy-1-[4-(2-phenylethenyl)phenyl]-3,5-di-O-(p-toluoyl)-p-**<u>erythro-pentitol (2e):</u>** A soln. of *p*-bromostilbene (= 1-bromo-4-(2-phenylethenyl)benzene; 1.444 g, 5.572 mmol) in THF (25 ml) was slowly added to Mg turnings (234 mg, 9.63 mmol). After the addition of 2 ml of the *p*-bromostilbene soln., I₂ crystals, and 2 drops of dibromoethane were added to start the reaction. The rest of the *p*-bromostilbene was added slowly, then the soln. was heated under reflux for 2 h. Subsequently, CdCl₂ (1.22 g, 6.67 mmol) was added and the mixture heated for another 2 h under reflux. After cooling to r.t., a soln. of chlorosugar (2.731 g, 6.686 mmol) was added slowly via a dropping funnel and stirred for 16 h. The soln. was dried in vacuo to remove the THF, the residue dissolved in CH₂Cl₂, and the soln. washed twice with aq. sat. NH₄Cl soln., dried (MgSO₄), and evaporated. Purification by FC (hexanes/AcOEt 7:1) gave 2.279 g (77%) of 2e. White powder. ¹H-NMR: 8.00 (*d*, *J* = 5.1, 4 H); 7.70 (*d*, *J* = 5.1, 2 H); 7.54 (*m*, 3 H); 7.42 (*m*, 3 H); 7.28 (*m*, 5 H); 7.27 (*m*, 2 H); 5.42 (*m*, 1 H); 5.40 (*t*, *J* = 4.2, 1 H); 4.68 (*m*, 1 H); 4.60 (*d*, *J* = 4.2, 2 H); 2.94 (q, J = 4.2, 1 H); 2.44 (s, 3 H); 2.42 (s, 3 H); 1.62 (s, 1 H); 1.28 (t, J = 4.5, 1 H). ¹³C-NMR: 144.7; 138.6; 137.1; 129.3 (2*s*); 128.9; 128.1; 127.2; 127.1; 126.8; 87.6; 80.1; 73.2; 45.3; 25.7; 25.5; 25.3; 25.1; 24.9. HR-MS: 532.3067 (C₃₅H₃₂O₅⁺, *M*⁺; calc. 532.2250).

(1S)-1,4-Anhydro-1,2-dideoxy-1-[4-(2-phenylethenyl)phenyl]-p-erythro-pentitol (3e):

According to *G.P. B*, with **2e** (203 mg, 0.381 mmol) and $0.5_{\rm M}$ NaOMe in MeOH (0.76 ml, 0.38 mmol) in MeOH/CH₂Cl₂ 2.5 : 1 (5 ml): 610 mg (75%) of **3e**. ¹H-NMR: 7.42 (*m*, 4 H); 7.24 (*dm*, 4 H); 7.08 (*m*, 2 H); 4.86 (*q*, *J* = 4.1, 1 H); 4.22 (*q*, *J* = 4.0, 1 H); 3.70 (*q*, *J* = 2.7), 3.68 (*q*, *J* = 2.7), 3.45 (*s*, 6 H); 2.46 (*q*, *J* = 4.1, 1 H); 1.72 (*m*, 2 H); 1.17 (*s*, 1 H). ¹³C-NMR: 166.4; 166.1; 143.9; 143.8; 141.8; 137.3; 136.5; 129.7; 129.6; 129.1; 129.0; 128.7; 128.6; 128.3; 127.6; 127.0; 126.8; 126.5; 126.4; 126.2; 126.0; 82.1; 81.9; 80.0; 76.3; 75.4, 65.1; 64.6; 55.2; 40.3; 39.2; 21.6. HR-MS: 296.1409 (C₁₉H₂₀O₃⁺, *M*⁺; calc. 296.1412).

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-[4-(2-

phenylethenyl)phenyl]-**p**-**erythro-pentitol (4e):** According to *G.P. C*, with (MeO)₂Tr-Cl (841 mg, 2.46 mmol), ⁱPr₂EtN (0.54 ml, 3.09 mmol), a spatula tip of DMAP, **3e** (610 mg, 2.058 mmol), and dry pyridine (10 ml), for 4 h. Purification by FC (silica gel preequilibrated with 5% Et₃N in hexanes; hexanes/AcOEt 6 :1 \rightarrow 1 : 2): 1.037 mg (84%) of **4e**. Light yellow foam. ¹H-NMR: 7.54 (*m*, 6 H); 7.45 (*m*, 13 H); 6.88 (*s*, 2 H); 6.86 (*s*, 2 H); 5.16 (*t*, *J* = 4.6, 1 H); 4.46 (*q*, *J* = 2.9, 1 H); 4.22 (*q*, *J* = 3.6, 1 H); 3.82 (*s*, 6 H); 3.43 (*q*, *J* = 2.9, 1 H); 3.27 (*dd*, *J* = 3.8, 2.1, 1 H); 2.72 (*q*, *J* = 3.9, 1 H); 1.97 (*d*, *J* = 2.8, 1 H); 1.61 (*s*, 1 H). ¹³C-NMR: 158.5; 144.8; 142.3; 137.3; 135.9; 130.0; 128.6; 128.5; 128.3; 128.1; 127.9; 127.6; 126.8; 126.6; 126.4; 126.1; 113.1; 86.3; 84.4; 79.5; 75.2; 64.7; 55.2; 43.0.

(1S)-1,4-Anhydro-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-1-[4-(2-phenylethenyl)phenyl]-p-erythro-pentitol 3-(2-Cyanoethyl

Diisopropylphosphoramidite) (5e): According to *G.P. D*, with 2-cyanoethyl diisopropylphosphoramidochloridite (0.578 ml, 2.59 mmol), ${}^{i}Pr_{2}EtN$ (1.2 ml, 6.9 mmol), **4e** (1.034 mg, 1.727 mmol) and CH₂Cl₂ (20 ml), for 4 h. Purification by FC (hexanes/AcOEt 3 : 1) gave 966 mg (70%) of **5e**. White foam. ${}^{1}H$ -NMR: 7.54 (*m*, 3 H); 7.41 (*m*, 7 H); 7.13 (*s*, 1 H); 6.86 (*dd*, *J* = 1.9, 3.7, 2 H); 5.16 (*t*, *J* = 4.6, 1 H); 4.60 (*dm*, 1 H); 4.39 (*q*, *J* = 2.6, 1

H); 3.81 (*s*, 6 H); 3.52 (*m*, 2 H); 3.29 (*m*, 4 H); 2.85 (*m*, 1 H); 2.20 (*m*, 1 H); 1.59 (*s*, 2 H); 1.15 (*m*, 6 H); 1.11 (*d*, J = 4.2); 1.05 (*d*, J = 4.2). ¹³C-NMR: 158.3; 144.8; 142.3; 137.3; 135.9; 130.1; 128.6; 128.5; 128.3; 128.1; 127.9; 127.6; 126.8; 126.6; 126.4; 126.1; 113.0; 86.3; 84.4; 80.0; 75.2; 64.7; 55.1; 42.7; 24.6.

5. Cyclohexene Nucleoside. (1S)-1,4-Anhydro-1-(cyclohex-1-en-1-yl)-1,2dideoxy-3,5-di-O-(p-toluoyl)-p-erythro-pentitol (2f)—A soln. of 1-di-O-(p-tolbromocyclohexene (1f; 2.090 g, 12.98 mmol) and 1,2-dibromoethane (900 µl, 10.44 mmol) in THF (40 ml) was slowly added to Mg turnings (647 mg, 26.62 mmol) in THF (10 ml). To start the *Grignard* reaction, the mixture was slightly heated. After complete addition of the bromo compound, the mixture was stirred for 2 h at 50°. ZnCl₂ (901 mg, 6.61 mmol) was added and the mixture stirred for 2 h under reflux. Then, the mixture was cooled to r.t. and a soln. of Hoffer's chlorosugar (5.076 g, 13.05 mmol) in THF (25 ml) added. After stirring for 16 h at r.t., the solvent was evaporated, the residue suspended in CH_2Cl_2 and washed twice with 10% NH₄Cl soln. The aq. layers were extracted with CH₂Cl₂ and the org. layers dried $(MgSO_4)$ and evaporated. Purification by FC (hexanes/AcOEt 6 : 1) gave 2.313 g (41%) of 2f. Colorless oil which contained *ca*. 13% of a double-bond isomer as an impurity. ¹H-NMR: 7.92 (m, 4 arom. H); 7.22 (m, 4 arom. H); 5.80 (m, 1 H); 5.50 (m, H – C(1)); 4.61, 4.53 - 4.44 (2m, H – C(3), H – C(4), 2 H – C(5)); 2.62 (m, 1 H – C(2)); 2.41, 2.39 (2s, 2) $MeC_{6}H_{4}$; 2.15 - 2.01, 1.67 - 1.54 (2m, 1 H – C(2), 8 H of chx). ¹³C-NMR: 166.3, 166.1 (2 C = O); 143.9, 143.7 (2s, 2 arom. C); 136.7 (s, 1 C of chx); 129.7, 129.6, 129.1, 129.0 (4d, 8 arom. CH); 127.1, 127.0 (2s, 2 arom. C); 123.6 (1d, 1 CH of chx); 82.5, 81.2, 76.3 (3d, CH(1), CH(3), CH(4)); 64.7, 36.4 (2t, CH₂(5), CH₂(2)); 24.9, 23.7, 22.5 (3t, 4 CH₂ of chx); 21.6 (q, $CH_3C_6H_4$). HR-MS: 435.2185 ($C_{27}H_{31}O_5^+$, $[M + H]^+$; calc. 435.2171).

(1S)-1,4-Anhydro-1-(cyclohex-1-en-1-yl)-1,2-dideoxy-p-erythro-pentitol (3f): According to *G.P. B*, with 2f (276 mg, 0.635 mmol) and $0.5_{\rm M}$ NaOMe in MeOH (630 µl, 0.315 mmol) in MeOH/CH₂Cl₂ 1 :1 (5 ml): 101 mg (80%) of 3f. Colorless oil. ¹H-NMR: 5.75 (br. *s*, 1 H of chx); 4.38, 4.29 (2*m*, H – C(1), H – C(3)); 3.83, 3.73, 3.65 (3*m*, H – C(4), 2 H – C(5)); 2.92, 2.68 (br. *s*, 2 OH); 2.29 (1*m*, 1 H – C(2)); 1.96 – 1.87, 1.67 – 1.54 (2*m*, 1 H – C(2), 8 CH of chx). ¹³C-NMR: 137.6 (1*s*, 1 C); 123.5 (1*d*, 1 CH); 84.7, 81.7, 72.6 (3*d*, CH(1), CH(3'), CH(4')); 62.3, 38.9 (2*t*, CH₂(5'), CH₂(2')); 24.9, 23.5, 22.4 (3*t*, 4 CH₂ of chx). HR-MS: 198.1252 (C₁₁H₁₈O⁺₃; calc. 198.1256).

(1S)-1,4-Anhydro-1-(cyclohex-1-en-1-yl)-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-_perythro-pentitol (4f): According to *G.P. C*, with (MeO)₂Tr-Cl (179 mg, 0.528 mmol), ⁱPr₂EtN (150 µl, 0.876 mmol), a spatula tip of DMAP, **3f** (85 mg, 0.428 mmol), and pyridine/CH₂Cl₂ 1 : 1 (5 ml), for 3 days. Purification gave 182 mg (85%) of **4f**. Colorless oil. ¹H-NMR: 7.35 (*m*, 2 arom. H); 7.25 - 7.09 (*m*, 7 arom. H); 6.74 (*m*, 4 arom. H); 5.67 (*m*, 1 H of chx); 4.32 (*t*, *J* = 7.4, H – C(1)); 4.18, 3.91 (2*m*, H – C(3), H – C(4)); 3.69 (*s*, 2 MeO); 3.23 (*dd*, *J* = 9.4, 4.6, 1H – C(5)); 3.03 (*dd*, *J* = 9.4, 6.4, 1 H – C(5)); 2.21 (*m*, 1 H – C(2)); 2.11 - 1.93 (*m*, 4 CH of chx); 1.81 (*m*, 1 H – C(2)); 1.64 - 1.44 (*m*, 4 CH of chx). ¹³C-NMR: 158.4, 144.8, 138.1, 136.0 (4*s*, 5 arom. C, 1 C of chx); 130.0, 128.1, 127.8, 126.7, 122.9, 113.1 (6*d*, 13 arom. CH, 1 CH of chx); 86.2 (*s*, 1 C); 83.9, 81.8, 75.1 (3*d*, CH(1), CH(3'), CH(4')); 64.9 (*t*, CH₂(5)); 55.2 (*q*, 2MeO); 40.7 (*t*, CH₂(2)); 24.9, 23.9, 22.5 (3*t*, 4 CH₂ of chx). HR-MS: 523.2480 (C₃₂H₃₆NaO₅⁺, [*M* + Na]⁺; calc. 523.2460).

(1S)-1,4-Anhydro-1-(cyclohex-1-en-1-yl)-1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-_{p-} erythro-pentitol 3-(2-Cyanoethyl Diisopropylphosphoramidite) (5f): According to *G.P.D*, with 2-cyanoethyl diisopropylphosphoramidochloridite (433 mg, 1.829 mmol), ⁱPr₂EtN (800 μ l, 4 mmol), 4f (586 mg, 1.170 mmol), and CH₂Cl₂ (10 ml). Purification gave 662 mg (81%) of 5f. White foam. ¹H-NMR (mixture of 2

diastereoisomers): 7.53 - 7.50, 7.42 - 7.17, 7.09 - 7.01, 6.93 - 6.91, 6.86 - 6.82 (5*m*, 20 arom. H); 5.43 (*m*, H – C(1)); 4.57, 4.34 (2*m*, H – C(3), H – C(4)); 3.81, 3.80 (2*s*, 2 MeO); 3.72 - 3.48, 3.38 - 3.27, 3.17 - 3.13 (3*m*, 2 Me₂CHN, OCH₂CH₂CN, 2 H – C(5)); 2.75 (*m*, 1 H – C(2)); 2.56 - 2.51 (*m*, OCH₂CH₂CN); 2.37 (*m*, 1 H – C(2)); 1.17 - 1.03 (*m*, 2 Me_2 CHN). ¹³C-NMR: 158.4, 146.1, 144.9, 137.1, 136.4, 136.1, 136.0 (7*s*, 10 arom. C); 130.1, 128.2, 127.9, 127.8, 126.7, 124.9, 124.4, 124.3, 124.0, 123.6, 123.2 (11*d*, 16 arom. CH); 117.5 (*s*, CN); 113.1 (*d*, 4 arom. CH); 86.1 (*s*, 1 C); 84.7, 76.3 (2*d*, CH(1), CH(4)); 75.0, 74.8 (2*d*, CH(3')); 63.8 (*t*, CH₂(5')); 58.2, 58.1 (2*t*, OCH₂CH₂CN); 55.2 (*q*, 2 MeO); 43.2, 43.1 (2*d*, 2 Me₂CHN); 42.4 (*t*, CH₂(2)); 24.6, 24.5, 24.4, 24.3 (4*q*, 2 Me_2 CHN); 20.1, 20.0 (2*t*, OCH₂CH₂CN). HR-MS: 723.3528 (C₄₁H₅₃N₂NaO₆P⁺, [*M* + Na]⁺; calc. 723.3539).

6. Absorption Spectra—Absorption spectra were measured for $10 \mu_M$ solns. in MeOH at r.t. on a *Cary*-I-UV/VIS spectrometer.

7. Emission Spectra and Quantum Yields—Fluorescence spectra of 10 μ_M solns. in MeOH (except for terthiophene 7, in CH₂Cl₂) were measured on a *SPEX-1680* double spectrometer at r.t. The solvents were deoxygenated by bubbling N₂ through the solvent for 2 h. The spectra were corrected for instrument response. All slits were set to 2 mm, resulting in a *ca.* 3.4-nm resolution. Fluorescence quantum yields (Φ_f) were calculated by the equation $\Phi_f = (FA_s \eta^2 \Phi_s)/(AF_s \eta_0^2)$, where the subscript s refers to the standard and Φ is the quantum yield, *F* the corrected, integrated fluorescence, *A* the absorption at the excitation wavelength, η the refractive index of MeOH (or CH₂Cl₂), and η_0 the refractive index of H₂O [30]. Quantum-yield standards were quinine sulfate (*Aldrich*, 99 + %, used without further purification), 10 μ_M in 1_N H₂SO₄ ($\Phi_f = 0.55$ [31] [32]), and fluorescein (*Aldrich*, recrystallized from 1_N NaOH by adding 10% AcOH/H₂O), 10 μ_M in 0.1_N NaOH ($\Phi_f = 0.90$ [31]).

Acknowledgments

We thank the U.S. Army Research Office for support, and the Swiss National Science Foundation for a 'Stipendium für angehende Forschende' to C.S. We also thank Joseph Langenhan for early work with the cyclohexene derivative.

REFERENCES

- a) Royer CA. Methods Mol. Biol. 1995; 40:65. [PubMed: 7633532] b) Wu P, Brand L. Anal. Biochem. 1994; 218:1. [PubMed: 8053542]
- Holzwarth A. Methods Enzymol. 1995; 246:334. [PubMed: 7752930] b) Millar DP. Curr. Opin. Struct. Biol. 1996; 6:637. [PubMed: 8913686]
- a) Beaucage SL, Iyer RP. Tetrahedron. 1993; 49:1925. b) Cunningham RE. Methods Mol. Biol. 1999; 115:271. [PubMed: 10098191]
- 4. a) Heyduk T, Ma Y, Tang H, Ebright RH. Methods Enzymol. 1996; 274:492. [PubMed: 8902827]
 b) Lundblad JR, Laurance M, Goodman RH. Mol. Endocrinol. 1996; 10:607. [PubMed: 8776720]
- a) Barrio JR, Secrist JA III, Leonard NJ. Biochem. Biophys. Res. Commun. 1972; 46:597. [PubMed: 4550694] b) Srivastava SC, Raza SK, Misra R. Nucleic Acids Res. 1994; 22:1296. [PubMed: 7513082]
- 6. Ward DC, Reich E, Stryer L. J. Biol. Chem. 1969; 244:1228. [PubMed: 5767305]
- 7. Allan BW, Reich NO, Beechem JM. Biochemistry. 1999; 38:5308. [PubMed: 10220317]
- Otto MR, Bloom LB, Goodman MF, Beechem JM. Biochemistry. 1998; 37:10156. [PubMed: 9665721]
- 9. Bujalowski W, Klonowska MM. Biochemistry. 1994; 33:4682. [PubMed: 8161526]

- Ren RXF, Chaudhuri NC, Paris PL, Rumney S, Kool ET. J. Am. Chem. Soc. 1996; 118:7671. [PubMed: 20865136]
- 11. Moran S, Ren RX-F, Sheils CJ, Rumney S, Kool ET. Nucleic Acids Res. 1996; 24:2044. [PubMed: 8668534]
- 12. Coleman RS, Madaras ML. J. Org. Chem. 1998; 63:5700.
- Erzberger JP, Barsky D, Scharer OD, Colvin ME, Wilson DM. Nucleic Acids Res. 1998; 26:2771. [PubMed: 9592167]
- 14. Paris PL, Langenhan JM, Kool ET. Nucleic Acids Res. 1998; 26:3789. [PubMed: 9685497]
- 15. Guckian KM, Schweitzer BA, Ren RXF, Sheils CJ, Paris PL, Tahmassebi DC, Kool ET. J. Am. Chem. Soc. 1996; 118:8182. [PubMed: 20882117]
- 16. Matray TJ, Kool ET. J. Am. Chem. Soc. 1998; 120:6191. [PubMed: 20852721]
- 17. Matray TJ, Kool ET. Nature (London). 1999; 399:704. [PubMed: 10385125]
- 18. Chaudhuri NC, Kool ET. Tetrahedron Lett. 1995; 36:1795.
- 19. Chaudhuri NC, Ren RXF, Kool ET. Synlett. 1997:341. [PubMed: 20336193]
- 20. Morvan F, Rayner B, Imbach J-L. Anticancer Drug Des. 1991; 6:521. [PubMed: 1772567]
- 21. Manoharan M, Tivel KL, Zhao M, Nafisi K, Netzel TL. J. Phys. Chem. 1995; 99:17461.
- 22. Mohanakrishnan AK, Lakshmikantham MV, McDougal C, Cava MP, Baldwin JW, Metzger RM. J. Org. Chem. 1998; 63:3105.
- 23. a) McKillop A, Bromley D, Taylor EC. J. Org. Chem. 1972; 37:88. b) Rossi R, Carpita A, Ciofalo M, Lippolis V. Tetrahedron. 1991; 39:8443. c) Bäuerle P, Würthner F, Götz G, Effenberger F. Synthesis. 1993:1099.
- 24. Cardona L, Fernandez I, Garcia B, Pedro JR. Tetrahedron. 1986; 42:2725.
- 25. Ndebeka G, Raynal S, Caubére P. J. Org. Chem. 1980; 45:5394.
- 26. Hoffer M. Chem. Ber. 1960; 93:2777.
- 27. Garcia P, Pernaut JM, Hapiot P, Wintgens V, Valat P, Garnier F, Delabouglise D. J. Phys. Chem. 1993; 97:513.
- 28. Telser J, Cruickshank KA, Morrison LE, Netzel TL. J. Am. Chem. Soc. 1989; 111:6966.
- 29. Lewis FD, Wu TF, Burch EL, Bassani DM, Yang JS, Schneider S, Jager W, Letsinger RL. J. Am. Chem. Soc. 1995; 117:8785.
- 30. Simpson DJ, Unkefer CJ, Whaley TW, Marrone BL. J. Org. Chem. 1991; 56:5391.
- 31. Demas JN, Crosby GA. J. Phys. Chem. 1971; 75:991.
- 32. Olmsted J. J. Phys. Chem. 1979; 83:2581.







Figure 1.


Absorption (—) and normalized emission spectra (- - -) of free nucleosides 3a - e at 10 μ_M concentration in methanol. Arbitrary intensity units for the emission spectra, with excitation at the absorption maxima.





Strässler et al.














Scheme 1.



Scheme 2.

Table 1

Absorption and Emission Data and Quantum Yields (Φ_f) for Nucleosides **3a** – **e** in Methanol

| | Absorption maxima [nm] | Extinction coeff. [m ⁻¹ cm ⁻¹] | Emission maxima [nm] | $\Phi_{\rm f}$ (excitation) [nm] |
|--|---------------------------|--|-------------------------|----------------------------------|
| 3a | 358 | 31400 | 432 | 0.059 (358) |
| 3b | 437 | 18300 | 536 | 0.67 (440) |
| 3c | 285 | 40100 | 345 | 0.42 (290) |
| 3d | 343 | 34400 | 377 | 0.025 (344) |
| 3e | 301 | 21100 | 356 | 0.055 (298) |
| Pyrene-1-butanoic acid | 343 | 33800 | 377 | 0.027 (344) |
| 2,2': 4',2"-Terthiophene (7) ^{<i>a</i>)} | 355 | 29900 | 431 | 0.063 (358) ^{b)} |

a) CH2Cl2 solvent.

b) The reported quantum yield is 0.055 [27].

NIH-PA Author Manuscript